Designing for Health: Interview with Mukul Mehra, MD [Podcast]

Low-value care are medical services that provide little to no benefit to patients and continues to be a pressing issue in healthcare. These interventions, such as redundant lab tests or unnecessary imaging, not only strain health system resources but can also lead to financial harm and therapeutic cascades for patients. This episode explores how clinicians can identify and reduce low-value care through real-time cost transparency, contextual nudging, and evidence-based decision support, ultimately promoting more efficient and patient-centered care.

On today’s episode of In Network's Designing for Health podcast, Nordic Chief Medical Officer Craig Joseph, MD, talks with Mukul Mehra, MD, gastroenterologist and founder of IllumiCare. They discuss the intersection of clinical care and financial stewardship. Dr. Mehra shares his journey from practicing medicine to launching a company aimed at reducing low-value care through contextual nudging and clinical financial decision support. They also discuss perspectives on how cost transparency, provider incentives, and thoughtful design can improve patient outcomes and reduce unnecessary spending without compromising clinical autonomy.

Listen here:

 

 

 

In Network's Designing for Health podcast feature is available on all major podcasting platforms, including Apple PodcastsAmazon MusiciHeartPandoraSpotify, and more. Search for 'In Network' and subscribe for updates on future episodes. Like what you hear? Leave a 5-star rating and write a review to help others find the podcast.

Want to learn more from Dr. Joseph? Order a copy of his book, Designing for Health. 

 

Show Notes:

[00:00] Intros

[01:36] Choosing gastroenterology

[02:49] The start of IllumiCare

[04:29] Uncovering low-value care

[09:14] The therapeutic cascade

[11:13] Building cost awareness

[17:15] Clinical financial decision support

[29:27] Incentivizing low-value care reduction

[38:05] Mukul’s favorite well-designed thing

[40:15] Outros

 

 

 

 

Transcript:

 

Dr. Craig Joseph: Doctor Mehra, welcome to the podcast. How are you today, sir?

Dr. Mukul Mehra: I'm great. Thanks for having me.

Dr. Craig Joseph: And where do we find you today?

Dr. Mukul Mehra: Birmingham, Alabama. That of the IllumiCare office.

Dr. Craig Joseph: Awesome. I look forward to hearing more about IllumiCare and how you got there. But let's start at the beginning. You've always, since you were a small child, have always wanted to run a company. Is that true?

Dr. Mukul Mehra: Absolutely. After the Apgar score of nine, I declared that I'm going to have a company in health care one day, and they downgraded me from a nine to a seven on the Apgar.

Dr. Craig Joseph: So are we talking about the one-minute Apgar or the five-minute Apgar? It's very important. Our listeners want to know.

Dr. Mukul Mehra: You know too much. It was the five-minute Apgar.

Dr. Craig Joseph: It was a five-minute Apgar. You got a nine. Well that's good, that's good. That's how you get into some of the best schools. So let's assume that we're both being sarcastic. And that's not what you've always wanted to do. You wanted to go to medical school, I presume, and become a physician.

Dr. Mukul Mehra: I love math and physics. It still has always been my passion. And so it was really the electrical engineering route that I thought I was going to go to. I went to school at northwestern, but I found the human connective within the medical profession as the ultimate, you know, guide towards picking medical school.

Dr. Craig Joseph: And you became a gastroenterologist. How does one choose that specialty? I was just curious. Is it the procedures? Is it the disease processes that you deal with, or is it just you fell into it?

Dr. Mukul Mehra: My uncle is a gastroenterologist. The certainly I grew up with a background in gastroenterology, but you're right. I enjoy a profession where your diagnostic skills were valued and you had therapeutic interventions doing a procedure, and you were. The procedure was to our design often in gastroenterology cedars in the morning and in the afternoon in patient rounding in between. That was ideal to me. That or cardiology, I chose gastroenterology. Electrophysiology fascinated me the most. Okay. It is the ultimate compendium of an amalgamation of the physics electrical pathways and the heart stopping or going haywire.

Dr. Craig Joseph: So you were an, are a practicing gastroenterologist. How did you get into this idea of starting a company and you know, what was that? What was that process like? What problems were you seeing?

Dr. Mukul Mehra: The biggest problem I saw was a buzzword called value-based care. And it was fascinating to me that we were going into value-based care, and we thought we had a pretty good handle on at least what we consider high quality. We didn't have a grasp of cost, especially at the provider level. We were going to enter value-based care and not fundamentally expose us to the people who actually are ordering therapeutics. That was a problem, and the biggest inspiration for me came when a patient who was a patient of mine, she had colon gyrus, who had renal failure, she had pancreatitis and sepsis. So me and four other physicians ever it was about an 11-day admission. But what really happened at the end of this 11-day admission is we saved her life.

I did a New York epi with this paradigm. It was a very hard what is done? And when she came back to the office six weeks or so later, when she looked distraught, she showed me her bill. And that began the journey of deconstructing a patient bill from an inpatient stay into line item for non-charges. Even the charges appear on these bills. So what is the true cause? Or as close as we get to the true cost of the things that we did to this patient, medication ordering AB ordering in graphics study ordering. And it was fascinating to me because I, I convened this group of five physicians back and I said, look, it took me a while, but I want us to do a chart review in retrospect.

And 43% of the stuff that we did to that patient, we admitted, was probably not needed. This is the problem, because a portion of that bill now hits the patient's wallet, and we know that low value care is problematic to health systems, but it's a real problem to the patient. It was fascinating to me. I had this moment where I was like, we've always talked about iatrogenic risks. I mean, it's a Greek word. Dietro means healer. Genic means the producer. So the healer produces unintended consequences from their therapeutic decisions upon a patient. Like we know this happens. There's been a recent article on excess imaging being done, and it's radiating our patients when we do CTS or we draw a lot of blood from a patient, you know, we make them anemic. Those are after genic risks. But the real risk now in 2025 is the financial consequences of what we're doing to our patients when we're ordering meds as radiographic studies, whatever they are, and they're low value.

Dr. Craig Joseph: Let's talk about low value care. I think outside of the clinical world it's a little confusing. These are not things that have no value that you shouldn't do. Right. You hurt your foot. So I get an X-ray of your arm like, no, probably that's no value. But low value care. Some things that we do that in high, like, as you mentioned, kind of in hindsight, maybe we didn't need. Can you share what are some examples of low value care that you see in your world of things that you might have done or might still do sometimes?

Dr. Mukul Mehra: Well, like that patient who had pancreatitis and a stone in the bile duct if she had pancreatitis. So we feel that we're going to order a lipids in any amylase and come back high. We've established the diagnosis of pancreatitis. There is no forecasting of recovery based on the potential levels of amylase in lipids. So it's low value. Does it feel good when their amylase and lipids come down? Sure. That's human nature. Yet you know it doesn't in any way portend other patients. And I do, because the definition of severe pancreatitis is not based upon lipids or amylase elevation. So it's always for one, you're ordering them sequentially. Two, you're ordering both of them sequentially. Each of these lab tests have a cause, by the way. They are an extraction of blood. And it's not super comfortable getting blood drawn. That's low value care. But we don't do it with any sinister motives as physicians.

Dr. Craig Joseph: I love that example, one that I've heard is ordering EKGs routinely before non-cardiac procedures. So you're having a knee replacement and well, we'll check your EKG just to be sure. Again, for patients who have no heart disease that is known, it seems like that wouldn't do any harm. And except for the money, of course it costs money, but it does cause harm, right? Because it's not been shown in studies to be helpful. The benefit doesn't outweigh the disadvantages. The disadvantages besides cost are hey, it takes more time. Hey. Inevitable we find something, and the conversation almost always goes like, yeah, I ordered this EKG. It's slightly abnormal. I'm not sure it means anything, but now I need the cardiologist to take a look and then the cardiologist as well.

It's probably nothing, but if you're going to have surgery, we should probably make sure it's not. And then let's order some more tests which delay the knee procedure that you were trying to get in the first place. And some of those tests involve being poked with needles, and having dye injected, and people have allergic reactions and other kinds of problems sometimes. And so these things that seem like, again, we call them low value, but sometimes they're actually harmful besides the money and the time. So it getting rid of them or minimizing those low value tests. Again you perfect with well you don't need lipids and MLA should probably only need one and you certainly don't need to check them every day to see that they're going down when you can tell the patient's doing well. Otherwise we have science. This is not just our idea. Right. There are there are studies that show that whether it's going down quickly or going down slowly doesn't really matter once you've established that you have a diagnosis and you're dealing with it the right way.

Dr. Mukul Mehra: Yeah, absolutely. That's I said, in fact, you're describing a longer-term harm, which is the therapeutic cascade. Like if you take that same patient okay. So now they went to see the cardiologist. The cardiologist orders a lipid panel as part of their workup. Well, the LDL is a little bit high. But now the LDL is high. So they get put on a stat, maybe the data on using statins for primary prevention with that LDL is not that high. I'm a hepatologist too. So now three months later, that patient's Alt is 68. Now they're coming to see me for elevated liver enzyme. And so the consequences of low value care and the therapeutic cascade of future unnecessary tests, it's very hard to quantitate the financial value or, you know, loss in that case. But, nevertheless, it's not by the patient or health care system.

Dr. Craig Joseph: I have not heard that term therapeutic cascade, but I love it. It reminds me of one of the things I used to tell parents as a pediatrician. I would tell them that my job was to do as little as possible for as long as possible, and I would have used the term therapy to prevent therapeutic cascade. Right. Because, well, should we get a lap? Well, if I get a CBC, something's coming back abnormal on that CBC and guarantee it. Right. And it might be a series of letters that I'm not even sure exactly what the MCT does, but there's an MCQ, and it's off by 0.1, and now, do I need to send you to the hematologist to make sure that's not the end?

And yeah, clearly, you've established you've helped us clarify that low value care is something to be avoided. And again, there's always circumstances where you do want to get a live piece in an MLS. And you might want to repeat those because the diagnosis is not clear. And so that now no one's talking about that. But we are talking about routinely doing things that really don't have any, science to support them. And so you saw that problem. How did you go about trying to solve it.

Dr. Mukul Mehra: First of all, the first challenge was surely somebody exposing clots to providers in the acute care setting. We can talk later about why we chose the acute care setting as our area to focus on and IllumiCare, but they weren't the cost accounting system. Data does not talk to the clinical ordering system in the electronic medical record. So for example, magnesium, you're acquiring 50 bottles of 20% stock solution of magnesium. Each of the bottles is 50ml. Well that's not how we order magnesium. As a physician we order to grant Mag Run IV that translation doesn't exist because we want to get to the actual acquisition cost of the magnesium, not what shows up on this bill. Discharge, Minister Bill and that translation is very, very difficult to do for medications, especially intravenous medications and drips.

It's not as hard to do for tablets, but the cost chain and for laboratory and for radiographic studies, you know, there's some proxy measures of cost for those. So, we begin to expose flaws at the point of care. If you expose them retrospectively or in an aggregated fashion, it tends to have very little meaning to physicians. And so, we had this challenge of, well, how do we put the cost right where the physician is, the electronic medical record, they're reviewing issue. That was going to be a challenge.

Dr. Craig Joseph: So yeah, the translation between the bulk and how that actually gets delivered to the patient, that's a problem that CFOs and folks in inventory management have been having forever, right? How much does it cost to take care of this patient for heart attack? I don't know, right? How much does the room cost? How much does the nurse cost? How high? Every lab value. We seem to know, but often are paid nowadays through a DRG, through a standard number. A patient has a heart attack that's worth x thousands of dollars, and we don't really care how much it costs you, the insurer or the government doesn't really care. Obviously, the hospital, the doc from the chief financial officer on down in does care. And so what were some of the things that kind of the problems that you've had in making that come true and in terms of being able to say to docs, hey, this is actually going to cost this much money, like, how do you how do you actually do it?

Dr. Mukul Mehra: So, if you make a physician log in, put in their password, find a patient lookup something, it's not going to work. We all know that. I mean, there's enough clicking around in the electronic medical record that putting a link or a hyperlink to expose clause wasn't going to work. So, the first attempt we had at exposing was to create an EMR agnostic ribbon that would surface the insight at the point of care that, hey, you're ordering is pace. Did you know it's this much? Or here's a receipt view of the things that you've ordered and it was fascinating to see how enlightening it was to physician to clinician that they could now, for the first time, see the cost of a lab cost of the medication at the dose they were giving per day. The putative cost of the radiology study. And it was really, really cool for like two months.

Dr. Craig Joseph: One thing I just want to call out that design kind of principle, that that learning principle, the way adults like to learn versus the way kids are forced to learn is, yeah, I'm happy to learn something. As long as it's at the time that I need to learn it. Right. And that's what that was, at least for the first two months. That was key. Don't tell me how much it cost for this other patient or for this other dose. And don't tell me before or after I've already done it. I you're telling me, as I'm about to order this thing, this is going to cost the patient this much. All right, so two months, it worked great. And should we end our story there, or is there more? Sounds like there might be more.

Dr. Mukul Mehra: And so the feedback would be that it began to have very little influence in low value care ordering beyond perhaps the Hawthorne effect. So maybe the daily CBCs would go down or the BMP would go down, or the CMP would go down. But ordering a hepatitis panel or ordering lipids and amylase again and again, it was very hard to prove that we were having an effect. And honestly, the physician feedback was, well, it was neat to see cause for a month or two, I think I got it. And we don't really pay as much attention to the past. And somebody came to me and said, it's really hard to think through an algorithm of care without knowing when you may be doing something low value. And amalgamating that with the clinical literature that proves it's low value. So, what I understood was, look, we're showing you cause it's too much of a cognitive load exercise for you to think through where costs are valuable. Like it's really not valuable to see the cost of levothyroxine, but the patient has hypothyroidism, the tablets generic consent. What are you going to do with that? It's there. Tylenol acetaminophen. It's $0.02 for a 500-milligram tablet. And so we had to begin to reduce the noise and build a data set that we called clinical financial decisions for.

Dr. Craig Joseph: Before we go on, let me just call out the Hawthorne effect that you referenced that some of our listeners might not be aware of what is the Hawthorne effect and how do you think it came into play?

Dr. Mukul Mehra: I mean, the Hawthorne effect is like when my wife says she really appreciates me folding the laundry, which I hardly ever do. But then when she comes in the house, I find some laundry and just start folding. But when she's not really looking, do I go around and fold laundry? No, but I should.

Dr. Craig Joseph: I've never heard it explain that way, the way I've typically read about it. I think it was a cumbersome factory, and either it was called Hawthorne or was in a location called Hawthorne, but they started doing some experiments by changing the lighting in the factory. And they changed. They made a brighter. And they found that productivity went up like, amazing, amazing. We changed the brightness made it brighter, productivity went up. Everyone should clearly now make everything brighter in the factory. And then they lowered it, you know, they left it that way for a while, then they lowered it, the lighting. And you know what? Productivity went up and the idea was, hey, if I perceive that you're doing some research on me or my work, that's around me, I'm going to be more attentive to whatever it is I'm doing.

And so whatever it is you're checking for, you might actually find it. And so it makes complete sense to me that all of a sudden there's, hey, this is how much that costs. Well, clearly the lesson I should learn from that is that I should take this into account and be better steward of my patients’ finances and not order something. So how do you make things? How do you design to take away from the noise? And just to your point, hey, if I don't have enough thyroxine, if I don't have that hormone, I need Synthroid, like I just need it or I'm not going to survive. And so whether it cost $0.10 a pill or $10 a pill, it's really not relevant because it's an expense that has to have. But there aren't. There are things where it is relevant. And so how do you pick those out?

Dr. Mukul Mehra: That is the hardest bit. So we have close to 1100 rules around medication lab and radiology ordering that take into account the cost of the therapeutic, the cost of some alternative to that, the clinical context that makes those relevant, and then a thorough review of the clinical literature. The goal is can you choose an ergative path? There's another med, another route of that med administration, another lab not doing that lab, another radiographic study, not doing that study and quality the outcome but still be the same or improve. And if you can do that and lower the pause in that process, we call that rule set our clinical financial decision support. So clinical decision support just says well look you come in with fib, you should check for all right abnormality. That's clinical decision support. Clinical financial decision support is hey you came in here, you have a DBA.

If you don't have renal failure and the pH is at less than 7.2, you shouldn't be using I.V. sodium bicarbonate. It feels really good to get the PH. I mean, who wouldn't want somebody to put it in their blood? PH is low. Yet the outcomes if the pH is low and the kidney function is normal, is that you will raise the pH but impart no value in terms of morbidity or mortality, the patient's admission. And then there's a cost. So, in that case you don't need to use sodium bicarb. You can use a less expensive crystalloid or I.V. fluid or not use one, that's clinical financial decision support. And not every clinical value rule makes it through the final of clinical financial decision support. That then has to be imparted contextually to the right provider who's ordering it or somebody in their specialties ordering it because they've left the service.

And there's some clinical parameter inside of the patient's clinical window that says, look, this is trading on potential low value care. And we never say no value care because we're not at the bedside. And you and I have both been at the bedside. We don't like people not at the bedside or technology not at the bedside, but make absolute declaration.

Dr. Craig Joseph: So I think what you've called this and you've just kind of given us a clue is contextual nudging. So of course, most of us know what a nudge is. Just a little push in the right direction. Which to your point, sometimes it's wrong. Sometimes. Yeah. This is not a nine out of ten. This is the one out of ten. And I don't want to do that. But make it easier to do the right thing. You push me a little bit, but the key is the context. And so knowing what you know, sounds like you've written these rules to say, hey, based on the context of what's going on, this might not be the best way. I think it's fascinating that example that you gave of, well, you want to get the pH back to normal. Doing so doesn't seem to actually benefit the patient in the short term, doing that quickly. And so you're simply doing something to make you feel better, but you're not actually doing something to make your patient feel better.

And that kind of nudging is completely appropriate. And so that just works in the ear. I just get that nudge. How does that work? Because it does. Does it differ based on the kind of electronic health record I'm using or is it, does it look like it's coming from inside the EHR? Who do I feel is nudging me?

Dr. Mukul Mehra: Well, it's meant to feel like the institution is nudging you. IllumiCare uses really a black framework to nudge, because we think providers have been anchored into ignoring native EMR-looking nudges, and their ephemeral physician autonomy is super important. Clinician autonomy is super important when physicians are super highly educated, often, and been to school longer than anybody at the health system or anybody you know, on the payer world. And so we enjoy autonomy. And the nudge actually appears when you're in that patient's chart, you're the right provider to address that therapeutic because it's within your discipline. And then the nudge disappears. It fades away in seven seconds. That isn't really the mechanism that exists when you put insight into the native EMR alert window. But we know that what's important is to use all of those modality.

So with Epic and with clients, we push our clinical financial decision support insight into the Epic open architecture. We built it alongside of Epic and alongside of other clients. And when does that more heavy-handed approach occur? It occurs when the data analytics show that you succumb to low value care within that order more. You're an outlier. So we look at low value care variation. Look I think clinical variation is kind of important, but it's always going to be there. We're not all pieces of substrate for building a car, Toyota or a Honda. We just don't understand enough about different phenotypes of patients. So there's going to be clinical variation. But if you're an outlier in low value care, in ordering I.V. bicarb in patients that don't have a low pH and an elevated creatine, then you potentially will get that as a hard stop inside of the EMR architecture. Otherwise it'll just be a passive nudge.

Dr. Craig Joseph: I think most of us don't realize how complicated it is because it's not a simple rule. If you do this, then that happens. It's also looking at my past history and looking at what the patient is in front of me because, boy, your point, is well taken alert fatigue a real problem. And if I'm constantly getting pop ups and constantly getting told things, especially if I disagree with them, A, I take them wrong or, B, I agree with them. But like, I was just about to do it and you're badgering me. I'm just going to start making those things go away and they're going to be less important and not there. Explain to me about the seven seconds, I'm fascinated by this. How did you come up with that idea? I assume it just, hey, I see it on the screen. If I want to react to it, I will. Much of the time I don't want to react to it, but it's now planted in my head at seven seconds. The right amount of time is 10s better. Have you done that kind of side by side research or you just kind of picked a number and gone with it?

Dr. Mukul Mehra: We picked a number and I get to use usually make here to. So seven seconds seemed just enough time to digest the content and not feel that it's in any way intrusive, but it's configurable. We had a health system come to us and say, we think 10s allows people to not be annoyed, but they actually will read the abstract because we make a concise statement about whatever the PH. You know, sodium bicarb is only beneficial if you're acid and you have evidence of renal compromise. Otherwise it’ll potentially provide low value and can be harmful. Here's the cost per day of that. Here's a link to the abstract. And so we can track all of this. And we can track if somebody makes a change in the electronic medical record where they discontinue sodium bicarbonate, or they discontinue sodium bicarbonate but offer lactate and Ringer's, and then we look at these windows of time within the nudge for that, for that efficacy. Because that is how we measure efficacy is how do you, are you responding to them, and there's two kinds of responses. There's an immediate response. And a long-term response that our API is for learning here.

Dr. Craig Joseph: Let's talk about physician incentives. Every clinician wants to do right by the patient. It's difficult to sometimes, financially or otherwise, incentivize stocks to do less care, right? And I could totally make the argument going back to the EKG or anything else that we've talked about from a quality perspective or a low value perspective that, well, you know, once I had a patient that's a, you know, you're in trouble when I start that way. I had this patient one time, because you know, what's coming, which is they didn't fit. You know, this was one where I actually was going to harm the patient by doing knee surgery, because we didn't know that they had a heart problem. And even though, yes, you're right, only 1 in 10,000 times does that help?

But, boy, that was my patient. And so, there's the incentive for me to want to never miss anything. I'm not really seeing the forest for the trees because of that. So are there customers of yours who have figured out some way of incentivizing, either through money or other ways of, hey, you're doing the right thing? We want to call you out.

Dr. Mukul Mehra: Yeah, absolutely. And it's a poor strategy for IllumiCare when we engage a partner of system to begin to think through that. Why? Because thinking through cost as part of your clinical algorithm, that's not going to save you time. I mean, there is... IllumiCare is not a time saver. The stewardship module we're discussing and whether it's a little bit of time or more than just a little bit of time that a provider is having to think through low value care suggestion. There is some cognitive load to that. And physicians and providers should be rewarded for that. The health systems like MultiCare was really a pioneering health system for us. They recognized that one of the five quality metrics that they have wasn't being achieved by their hospitalist. And it was very frustrating. It's one that was honestly a metric that the providers didn't think they had complete control over.

The health system had a tough time tracking, so they scrapped it and they replaced it with low value care reduction. And we did data modeling on what is their low value care ordering before IllumiCare, you know, had gone live and what is the threshold that they would have to reach. And if you reach it allows the bonus. So, it is not just incentivizing reduction of care. It's really curbing low value care. And that is a real quality metric because of all of the reasons that we had discussed the consequences of low value care to the patient. And providers were like, well, I totally contract is. And by the way, in real time, I'm seeing these suggestions, and I'm not expected to follow all of them. You allow me a window of adjudication, understanding that not all of these are clinically relevant. And then there's techniques like there's a team effect. I'm a big fan of building incentives that are a team effect, because if one provider is like, whatever, I don't care. I don't care if it hurts the patient, don't care if it hurts the health system.

I'm tired and overworked. That's fine. I don't care about my bonus. Well, now you're having an effect on the whole team of hospitals. So, they're models that, look, you're part of a team. And really, honestly, the whole system in the patient or part of your team, but you're part of a more immediate team. All of your other hospital is. So if you want to take a reduction of low value care, you're actually hurting the rest of your team that is taking this scores on. And that is a fundamental model that we lead with in the engagement phase of IllumiCare. Discussing this with the health system. And they can't always pull it off right when IllumiCare goes live. But it's somewhere on the path, the happy path of fine in 6 to 9 months when it's up for negotiation. Let's do this though.

Dr. Craig Joseph: What about putting various physician ranking physicians I have found, and this might be a shocker to you. And I believe you're sitting. I found that physicians are very competitive. Is this a shocker to you? Are you still are you still with us or do you. Yeah. No, I think it's, it's a well-known fact, and I, I've, I have seen physicians who have that kind of attitude that you just described of. I don't think this is important. I don't think this is really valuable for my patient. And I'm not going to participate in this at all. And then they someone has the courage or stupidity to put up a list of, 100 doctors in the group, ranking them from most consistent with what we want them to do to least consistent with names and potentially numbers.

And, boy, I have seen physicians who are like, I still think this is dumb. I still don't see any purpose, but there's no way I'm going to let that guy outscore me on anything, because I don't think that guy's that smart. I'm going to beat him even though I don't. I don't care why. I just want to beat him. Have you used any of those perspectives?

Dr. Mukul Mehra: We do. We have an app. So after about 100 days of being live with the nudge technology, every provider can see their low value care spend for admission compared to their service. But we don't expose all the names for any one provider. But the leadership chief quality officer or chief medical officer do get a list of those providers. And like it was fascinating. There was one provider who would order magnesium the day after. One had been normal 1084 times in the last six months. He was a clear outlier, but other hospitals were doing the same thing too, just not that many times. Even when we ranked it by its mix index. We exclude patients in these detailed analysis like it couldn't have been on a magnesium drip.

They couldn't have been on, you know, an obstetrics service. So why is it still happening? And at that point, it's not IllumiCare who's going to be any more effective. It's really going to be somebody at the leadership level saying, did you know, like you are by far an outlier in repetitive magnesium load in patients, not on TPA and not on magnesium groups like, why do you do this?

Oh, and by the way, we have the stats that 97% of the time that they reordered it, it was still normal. So that's how you empower you. No change in no doubt. But I mean, one of the seminal experiments I did before IllumiCare is as an ERC physician, I knew we didn't have to. And these were outpatients. Use a stent pusher to push a stent up when you do a thing. I mean, you cut the sinker so that you can extract a stone. You just saved your sinker toe. Don't throw it away. And then when it's time to push a stent up, you just use the sphincter tone, but the stent on top of it and push the stand up.

Well, the stent pusher from the manufacturer. I looked up as I was curious, what is a stent pusher cost? It was $104. And so I began to create a list of $104. Who's using stent pushers? Who uses them the most? So I of course use none. And within six months we stopped ordering stent pushers in the GI line. None of this savings goes back to the physician. But people would come up to me and say, well, how do you, what is that? If you're not using a stent pusher? And I would show them, I'm doing any RCP, I'll show you, because nobody wanted to be the physician that was now responsible for ordering stent pushers. And when we go back to the GI lab, we reduced that pusher ordering and the expensive stent pushers so much that we felt comfortable asking the finance team for a collegiate scope. Oh, look, if we're saving $60,000 a year on stent pushers, we didn't need them. And the college's system is $40,000. You know, we felt empowered to asking for that. And these are the alignment and synergies that are needed in healthcare or propagating stewardship or low value care reduction so that all the entities involved, it's a win, the health system, the patient, and then the providers. So these are the ways that we model incentives even for subspecialists to like if you do these things, look, the next time you need something, the finance committee will say, well, look, you want this, you want another AP. We need to see some more efficiencies here. Perhaps we can get you an inpatient hospitalist AP down the road. And this is called alignment, which, you know, we've always been a misaligned health care system.

Dr. Craig Joseph: Alignment is essential to get everyone kind of rowing in the same direction. It sounds easy often, but boy, when you understand how the health care system works in the United States, when I say health care system with air quotes to get everyone kind of working as a team and making sure that people are paid and recognized for their good work and good deeds is complicated.

We could talk about this for another hour or two, but we have unfortunately run out of time. We like to always end with the same question, are there things that you deal with every day that are so well designed, it brings you joy when you deal with it?

Dr. Mukul Mehra: Something I use every day that is super well designed is honestly, it's the swimming pool.

Dr. Craig Joseph: The swimming pool.

Dr. Mukul Mehra: Yes. It is not technology. I don't know if the answer is supposed to be technology.

Dr. Craig Joseph: Oh no. But go on, I'm not stopping you. I want to hear.

Dr. Mukul Mehra: So this beautiful construct, which in America tends to be 25 yards long. And in some parts of America and in Europe, it's 25 to 50 m. If you're lucky, it has this black line and it is so consistent. It has four walls. And to me, I took up swimming as a way to break the cycle of overthinking when you just needed moments of mental relaxation. And it was very hard for me as a physician, you have your cell phone and IllumiCare book and get ahold of you all the time. And underwater nobody could get ahold of me. And during that hour I just find the ultimate therapeutic exercise to me is to go jump off the blocks, swim the 25 yards, do a flip turn which I didn't know how to do eight years ago. But I learned and it's a very consistent experience. The walls, the same, water buoyancy is the same and you can make it as challenging as you want. You can swim butterfly and you'll get short of breath pretty fast. Insulin breath stroke and breathe out of water all day long. But it's therapeutic. It's consistent. And it was a challenge I took up and I never grew up swimming.

Dr. Craig Joseph: But I love it. And what the black line you mentioned a black line that's at the bottom of the pool.

Dr. Mukul Mehra: It is. It's the center of the lane. Your goal is to swim center. You come off the wall and you're not center. So if you swim 25 yards and swim 25 back and you got off of that black line, you may swim 50.1 yard. If you're shooting for time and efficiency and consistency, the black line’s consistent. You weren't consistent because you didn't stay down the middle.

Dr. Craig Joseph: Yeah, obviously I'm not a swimmer because I'm asking what the black line is, but, no, that's great. I love that this has been great and what a great conversation. Thank you for teaching me and kind of explaining some things about how you've done your work, and I wish you only more success. And we'll have to check back in with you in a couple years to see what new things you've learned and how you've changed people to make it easy to do the right thing.

Dr. Mukul Mehra: But I learned from you, Craig, too. And thanks for having me on.

READ THE TRANSCRIPT

Topics: featured, Healthcare, podcast

Module heading text

Get the highest quality chemistry and microbiology testing services aligned closely with current good manufacturing practices (CGMP) for all types of products across all phases of development.

Subscribe to receive blog updates